Shares of Ireland-headquartered biotech firm Alkermes (Nasdaq: ALKS) closed up 2.6% to $60.93, having risen as much as 5% yesterday, after the company has released positive top-line results from the FORWARD-1 study.
This is one of a series of supportive clinical studies in the comprehensive FORWARD Phase III pivotal program for ALKS 5461, a once-daily, oral investigational drug with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
The FORWARD-1 study was designed to evaluate the safety and tolerability of two titration schedules of ALKS 5461. In addition, the study assessed the efficacy of ALKS 5461 over an eight-week period, compared to baseline, in patients with MDD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze